Amgen Inc. on Friday announced that the company has appointed Ellen Kullman to its board of directors, expanding it from 13 to 14 members. In her new role, effective immediately, Kullman will serve on the audit committee as well as its governance and nominating committee for the Thousand Oaks biotech. Kullman is a director for technology products and service provider United Technologies Corp. of Farmington, Conn. She has also served as a director for General Motors Co. of Detroit and was previously chief executive of E.I. du Pont de Nemours and Co., a Wilmington, Del.-based science and technology company. “We are pleased to welcome Ellen Kullman to the Amgen board,” Chief Executive Robert Bradway said in a statement. “Ellen’s deep experience in high-technology global businesses with strong regulatory oversight will be invaluable to Amgen as we grow our business and pursue our mission to serve patients.” Amgen shares closed up 72 cents, or less than 1 percent, to $162.62 on the Nasdaq.
